EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF

Matthew W Segar, Neil Keshvani, Sumitabh Singh, Lajjaben Patel, Shyon Parsa, Traci Betts, Gordon R Reeves, Robert J Mentz, Daniel E Forman, Mehdi Razavi, Mohammad Saeed, Dalane W Kitzman und 1 weitere

JACC: Heart Failure · 2024

DOI: 10.1016/j.jchf.2023.06.009 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Heart Failure, 2024. Verfasst von Matthew W Segar und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Texas Heart Institute, Houston, Texas, USA. Hauptthemen laut MEDLINE: Heart Failure, Defibrillators, Implantable, Frailty. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Implantable cardioverter-defibrillator (ICD) therapy is recommended to reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF). Frailty is common among patients with HFrEF and is associated with increased mortality risk. Whether the therapeutic efficacy of ICD is consistent among frail and nonfrail patients with HFrEF remains unclear. OBJECTIVES: The aim of this study was to evaluate the effect modification of baseline frailty burden on ICD efficacy for primary prevention among participants of the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). METHODS: Participants in SCD-HeFT with HFrEF randomized to ICD vs placebo were included. Baseline frailty was estimated using the Rockwood Frailty Index (FI), and participants were stratified into high (FI > median) vs low (FI ≤ median) frailty burden groups. Multivariable Cox models with multiplicative interaction terms (frailty × treatment arm) were constructed to evaluate whether baseline frailty status modified the treatment effect of ICD for all-cause mortality. RESULTS: The study included 1,676 participants (mean age: 59 ± 12 years, 23% women) with a median FI of 0.30 (IQR: 0.23-0.37) in the low frailty group and 0.54 (IQR: 0.47-0.60) in the high frailty group. In adjusted Cox models, baseline frailty status significantly modified the treatment effect of ICD therapy (Pinteraction = 0.047). In separate stratified analysis by frailty status, ICD therapy was associated with a lower risk of all-cause mortality among participants with low frailty burden (HR: 0.56; 95% CI: 0.40-0.78) but not among those with high frailty burden (HR: 0.86; 95% CI: 0.68-1.09). CONCLUSIONS: Baseline frailty modified the efficacy of ICD therapy with a significant mortality benefit observed among participants with HFrEF and a low frailty burden but not among those with a high frailty burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureDefibrillators, ImplantableFrailtyHumansFemaleMiddle AgedAgedMaleStroke VolumePrimary PreventionDeath, Sudden, CardiacRisk Factors

Stichwörter der Autor:innen

frailtyheart failureimplantable cardioverter-defibrillator

Autor:innen und Institutionen

  • Department of Cardiology, Texas Heart Institute, Houston, Texas, USA.
  • Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • School of Health Professions, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Heart and Vascular Institute, Novant Health, Charlotte, North Carolina, USA.
  • Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
  • Department of Medicine (Divisions of Cardiology and Geriatrics), University of Pittsburgh, Pittsburgh, Pennsylvania, USA; Geriatrics, Research, Education, and Clinical Care, Veterans Affairs Pittsburgh Healthcare System…

Zitieren

APA

Segar, M. W., Keshvani, N., Singh, S., Patel, L., Parsa, S., Betts, T., Reeves, G. R., Mentz, R. J., Forman, D. E., Razavi, M., Saeed, M., Kitzman, D. W., & Pandey, A. (2024). Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF. JACC: Heart Failure. https://doi.org/10.1016/j.jchf.2023.06.009

Vancouver

Segar MW, Keshvani N, Singh S, Patel L, Parsa S, Betts T, et al. Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF. JACC: Heart Failure. 2024. doi:10.1016/j.jchf.2023.06.009

BibTeX
@article{Segar2024,
  author = {Segar, Matthew W and Keshvani, Neil and Singh, Sumitabh and Patel, Lajjaben and Parsa, Shyon and Betts, Traci and Reeves, Gordon R and Mentz, Robert J and Forman, Daniel E and Razavi, Mehdi and Saeed, Mohammad and Kitzman, Dalane W and Pandey, Ambarish},
  title = {Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF},
  journal = {JACC: Heart Failure},
  year = {2024},
  doi = {10.1016/j.jchf.2023.06.009}
}
Kostenlos starten →